Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.

نویسندگان

  • Patricia Coelho de Soarez
  • Ana Marli C Sartori
  • Laura de Andrade Lagoa Nóbrega
  • Alexander Itria
  • Hillegonda Maria Dutilh Novaes
چکیده

OBJECTIVE To analyze the cost-effectiveness of a meningococcal C vaccination program in Brazil. METHODS A hypothetical cohort of 3,194,038 children born in Brazil in 2006 was followed for 10 years. A decision tree model was developed using the TreeAge Pro 2007 software program to compare universal infant vaccination with the current program. Epidemiological and cost estimates were based on data retrieved from National Health Information Systems and the literature. The analysis was conducted from the public health care system and societal perspectives. Costs are expressed in 2006 Brazilian reals (R$). RESULTS At 94% coverage, the program would avoid 1,218 cases, 210 deaths, and 14,473 life-years lost, a reduction of, respectively, 45%, 44%, and 44%, for the 10-year period. Vaccination costs of R$320.9 million would not be offset by R$4 to R$7.9 million decreases in disease treatment costs. A national vaccination program would cost R$21,620 per life-year saved from the perspective of the health-care system and R$21,896 per life-year saved from society's perspective. Results were most sensitive to case fatality rate, disease incidence, and vaccine cost. CONCLUSIONS A universal childhood vaccination program against meningococcal C proved to be a cost-effective strategy, supporting the recent decision of the Brazilian government. These results could contribute to defining the most favorable price of the vaccine and to monitoring its impact on the population.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines.

OBJECTIVES To assess the epidemiology of meningococcal disease (MD) in Brazil and the impact that recent evidence and lessons learned from the introduction of meningococcal C conjugate (MCC) vaccines into immunization programs may have on different strategies of vaccine use. SOURCES Non-systematic review of the MEDLINE, SciELO and LILACS databases covering the period from 2000 to 2011. SUMM...

متن کامل

Prevention of meningococcal infections in the first 2 years of life.

The spectrum of disease caused by Neisseria meningitidis includes bacteremia, fulminant sepsis (meningococcemia), meningitis, and pneumonia. The incidence of meningococcal infection has long been higher in infancy than adolescents or adults older than 65 years (a third group with an increased risk based on age). Five meningococcal serogroups (A, B, C, Y, and W135) cause the great majority of hu...

متن کامل

Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.

BACKGROUND In Italy one third of bacterial meningitis are caused by Neisseria meningitidis. In March 2005, the Regional Health Authority of Tuscany included the meningococcal serogroup C conjugate (MCC) vaccine in the recommended vaccination program with a schedule of three doses to all newborns at 3, 5 and 13 months of age (from 2008 amended to a single dose at 13 months) and a single catch-up...

متن کامل

4CMenB vaccine effectiveness: reasons for optimism.

Preventing invasive meningococcal disease (IMD) caused by the bacterial pathogen Neisseria meningitidis is of critical public health importance given the sudden onset of symptoms, rapid progression to serious disease, and high risk of mortality even among previously healthy individuals1,2. The burden of IMD has been reduced in many parts of the world through extensive public health efforts, mos...

متن کامل

Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands

BACKGROUND In 2002, vaccination with a serogroup C meningococcal conjugate vaccine (MenC) was introduced in the Netherlands for all children aged 14 months. Despite its success, herd immunity may wane over time. Recently, a serogroup A,C,W135,Y meningococcal conjugate vaccine (MenACWY) was licensed for use in subjects of 12 months of age and above. OBJECTIVES To evaluate the cost-effectivenes...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

دوره 14 8  شماره 

صفحات  -

تاریخ انتشار 2011